RC148

DRUG3 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Advanced Solid TumorBreast CancerNon-Small Cell Lung Cancer

Phase 1

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

RecruitingNCT06038396

RemeGen Co., Ltd.Advanced Solid Tumor

Start: 2023-08-03End: 2026-08-31Target: 48Updated: 2025-01-29

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Active, not recruitingNCT06883630

RemeGen Co., Ltd.Non-Small Cell Lung Cancer

Start: 2025-03-13End: 2027-07-31Updated: 2026-03-05

Phase 2

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

RecruitingNCT06642545

RemeGen Co., Ltd.Breast Cancer

Start: 2025-02-10End: 2027-10-01Target: 40Updated: 2025-02-17

Related Papers

Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study.

Journal of Clinical Oncology2025-05-28